RNAi Screening of the Kinome to Identify Mediators of proliferation and trastuzumab (Herceptin) resistance in HER2 Breast Cancers
Breast cancers with overexpression or amplification of the HER2 tyrosine kinase receptor are more aggressive, resistant to chemotherapy, and associated with a worse prognosis. Currently, these breast cancers are treated with the monoclonal antibody trastuzumab (Herceptin®). Unfortunately, not all pa...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/35712 |